Pharmacological treatment of cachexia: Any progress?

Supportive Care in Cancer

Volumn 6, Issue 2, 1998, Pages 109-113

  Bruera, Eduardo ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

Anorexia; Cachexia; Cancer; Clinical trials; Drug treatment

Indexed keywords

ANABOLIC AGENT; CANNABINOID DERIVATIVE; CLENBUTEROL; CYPROHEPTADINE; MEGESTROL ACETATE; MELATONIN; METOCLOPRAMIDE; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PROKINETIC AGENT; THALIDOMIDE; TUMOR NECROSIS FACTOR ANTIBODY;

ANOREXIA; CACHEXIA; CANCER PATIENT; CLINICAL TRIAL; DRUG EFFECT; DRUG INDICATION; DRUG RESEARCH; DRUG SCREENING; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; REVIEW;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTIEMETICS; ANTIOXIDANTS; APPETITE STIMULANTS; CACHEXIA; CLENBUTEROL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MEGESTROL ACETATE; MELATONIN; METOCLOPRAMIDE; NEOPLASMS; THALIDOMIDE;

EID: 0031887268     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050143     Document Type: Review

References (36)

1. Bruera E, MacDonald RN (1988) Nutrition in cancer patients: an update and review of our experience. J Pain Symptom Manage 3:133-140
2. Dunlop R (1996) Clinical epidemiology of cancer cachexia. In: Bruera E, Higginson I (eds) Cachexia-anorexia in cancer patients, vol 5. Oxford University Press, Oxford, pp 76-82
3. Fainsinger R (1996) Pharmacological approach to cancer anorexia and cachexia. In: Bruera E, Higginson I (eds) Cachexia-anorexia in cancer patients, vol 9. Oxford University Press, Oxford, pp 128-140
4. Billingsly KG, Alexander HR (1996) The pathophysiology of cachexia in advanced cancer and AIDS. In: Bruera E, Higginson I (eds) Cachexia-anorexia in cancer patients, vol 1. Oxford University Press, Oxford, pp 1-22
5. Bruera E, Fainsinger RL (1993) Clinical management of cachexia and anorexia. In: Doyle D, Hanks G, MacDonald N (eds) Oxford textbook of palliative medicine, sect 4.3.6. Oxford Medical London, pp 330-337
6. Plata-Salamon C (1996) Anorexia durins acute and chronic disease. Nutrition 12(2):69-78
7. Chlebowski RT, Bulcavate L, Grosvenor M, et al (1990) Hydrazine sulfate influence on nutritional status and survival in non small cell lung cancer. J Clin Oncol 8:9-15
8. Loprinzi CL, Juross SA, O'Fallon JR, et al (1994) Randomized placebo-controlled evaluation on hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 12:1121-1125
9. Loprinzi CL, Goldberg RM, Su JQ (1994) Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 12:1126-1129
10. Kosty MP, Fleishman SB, Herndon JE, et al (1994) Cisplatin, vinblastine and hydrazine sulfate in avanced non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the cancer and leukemia group B. J Clin Oncol 12:1113-1120
11. Noel P, Nelson S, Bokullic R, et al (1990) Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and morality. Life Signs 47:1023-1029
12. Goldberg RM, Loprinzi CL, Mailliard JA, et al (1995) Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 13:2856-2859
13. Nobel RE (1969) Effect of cyproheptadine on appetite and weight gain in adults. JAMA 209:2054-2055
14. Kardinal C, Loprinzi CL, Schaid DJ, et al (1990) A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657-2662
15. Bruera E, Catz Z, Hooper R, Lentle B, MacDonald RN (1987) Chronic nausea and anorexia in patients with advanced cancer: a possible role for autonomic dysfunction. J Pain Symptom Manage 2:19-21
16. Pereira J, Bruera E (1996) Chronic nausea. In: Bruera E, Higginson I (eds) Cachexia-anorexia in cancer patients, vol 2. Oxford University Press, Oxford, pp 23-37
17. Gralla RJ, Itri LM, Pisko SE, et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905-909
18. Bruera E, MacEachern T, Spachynski K, LeGatt D, MacDonald RN, Babul N, Harsanyi Z, Darke A (1994) Comparison of the efficacy, safety and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer 74:3204-3211
19. Loprinzi CL, Michalak JC, Schaid DJ (1993) Phase three evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/ or cachexia. J Clin Oncol 11:762-767
20. Loprinzi CL, Schaid DJ, Dose AN, et al (1993) Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 11:152-154
21. Bruera E, Ernst S, Hagen N, Spachynski K, Belzile M, Hanson J (1996) Symptomatic effects of megestrol acetate (MA): a double-blind, crossover study. Proc Am Soc Clin Oncol 1716:531
22. De Conno F, Martini C, Caraceni A, et al. Megestrol acetate for anorexia in patients with advanced cancer. Personal communication - submitted for publication
23. Tattersall MH (1995) Tumor-related cachexia and the role of megestrol acetate (Abstract). 7th International Symposium on Supportive Care in Cancer. September 20-23, 1995. Eur J Cancer 12
24. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R (1985) Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751-754
25. Schmidt H, Rush B, Simonian G, et al (1996) Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats. J Surg Res 63:143-146
26. Schufer U, Ehninger G (1995) Thalidomide: rationale for renewed use in immunological disorders (review). Drug Safety 12:364-369
27. Tramontana JM, Utaipat U, Molloy A, et al (1995) Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1:384-397
28. Kaplan G (1994) Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology 191:564-568
29. Lissoni P, Barni S, Tancini G (1994) Role of the pineal gland in the control of macrophage functins and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin. J Biol Regul Homeost Agents 8:126-129
30. Brackowski R, Zubelewicz B, Romanowski W, et al (1994) Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin. J Biol Regul Homeost Agents 8:77-80
31. Salleras L, Dominguez A, Mata E, et al (1995) Epidemiologic study of an outbreak of clenbuterol poisoning in Catalonia, Spain. Public Health Rep 1110:338-342
32. Rehfeldt C, Weikard R, Reichel K (1994) The effect of the beta-adrenergic agonist clenbuterol on the growth of skeletal muscles of rats. Arch Tierernahr 45:333-344
33. Young OA, Watkins S, Oldham JM (1995) The role of insulin-like growth factor I in clenbuterol-stimulated growth in growing lambs. J Anim Sci 73:3069-3077
34. Zhou GH, Han ZK (1994) Effects of dietary supplementation of beta 2-adrenergic agonist clenbuterol on carcase characteristics and some metabolites in ducks. Br Poultry Sci 35:355-361
35. Costelli P, Garcia-Martinez C, Llovera M, et al (1995) Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP ubiquitin-dependent proteolytic pathway. J Clin Invest 95:2367-2372
36. Maltin CA, Delday MI, Watson JS, Heys SN, Nevison IM, Ritchie IK, et al (1993) Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci 84:651-654